



(51) International Patent Classification:
C07K 16/18 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:
PCT/US2022/078913

(22) International Filing Date:
28 October 2022 (28.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/263,204 28 October 2021 (28.10.2021) US

(71) Applicant: **ABBVIE INC.**, [US/US]; 1 N. Waukegan Road,
AP34-2 V377, North Chicago, IL 60064 (US).

(72) Inventors: **LIAO, Fan**; 20 Gorham Road, Belmont, MA
02478 (US). **CHHAYA, Meha**; 12 Bittersweet Circle,
Shrewsbury, MA 01545 (US). **MCCLUSKEY, Andrew**;
27 Patriot Way, Holden, MA 01250 (US). **BROWN,
Nathan**; 45 Moore Road, Wayland, MA 01778 (US).

(74) Agent: **JOHANNES, Laura** et al.; c/o AbbVie Inc.,
AP34-2 V0377, 1 North Waukegan Road, North Chicago,
IL 60064 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: ANTI-AMYLOID BETA ANTIBODIES AND METHODS OF USING THE SAME




FIG. 1

(57) Abstract: The present inventive concept is related to antibodies, such as recombinant humanized and monoclonal antibodies, methods of making antibodies, and methods of using antibodies, such as antibodies directed toward and capable of specifically binding to and clearing amyloid-beta (A β) plaques in the brain that are suitable for use in the treatment of disorders such as Alzheimer's Disease (AD).

[Continued on next page]



SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*